Investigator Sripal Bangalore, MD, MHA summarizes the results of the ISCHEMIA-CKD EXTEND trial, which found that an invasive strategy of adding cardiac catheterization and revascularization to guideline-directed medical therapy does not reduce the 5-year risk of death compared to a conservative strategy in patients with advanced CKD and chronic coronary disease.